| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 124 | 2023 | 4849 | 6.040 |
Why?
|
| Glioma | 74 | 2023 | 1963 | 5.560 |
Why?
|
| Glioblastoma | 55 | 2022 | 1797 | 2.950 |
Why?
|
| Central Nervous System Neoplasms | 11 | 2020 | 502 | 2.000 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 18 | 2020 | 89 | 1.960 |
Why?
|
| Astrocytoma | 18 | 2020 | 321 | 1.710 |
Why?
|
| Isocitrate Dehydrogenase | 11 | 2020 | 480 | 1.520 |
Why?
|
| Biomarkers, Tumor | 36 | 2020 | 10331 | 1.090 |
Why?
|
| Cerebral Ventricle Neoplasms | 4 | 2023 | 81 | 1.000 |
Why?
|
| Pituitary Neoplasms | 8 | 2019 | 203 | 0.980 |
Why?
|
| Histones | 8 | 2019 | 1466 | 0.980 |
Why?
|
| STAT3 Transcription Factor | 16 | 2022 | 1121 | 0.880 |
Why?
|
| Mutation | 19 | 2020 | 15179 | 0.880 |
Why?
|
| Magnetic Resonance Imaging | 45 | 2023 | 7702 | 0.870 |
Why?
|
| Pineal Gland | 3 | 2017 | 50 | 0.810 |
Why?
|
| X-linked Nuclear Protein | 3 | 2019 | 56 | 0.800 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2019 | 62 | 0.790 |
Why?
|
| World Health Organization | 5 | 2020 | 316 | 0.750 |
Why?
|
| Activating Transcription Factor 1 | 1 | 2020 | 21 | 0.740 |
Why?
|
| Gene Expression Regulation, Neoplastic | 41 | 2022 | 8873 | 0.730 |
Why?
|
| Chromosomes, Human, Pair 1 | 6 | 2017 | 327 | 0.730 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2020 | 98 | 0.720 |
Why?
|
| Humans | 228 | 2023 | 261506 | 0.710 |
Why?
|
| Myxoma | 1 | 2020 | 63 | 0.710 |
Why?
|
| Cerebellar Neoplasms | 5 | 2020 | 434 | 0.710 |
Why?
|
| Ganglioglioma | 3 | 2014 | 41 | 0.700 |
Why?
|
| Chromosomes, Human, Pair 19 | 4 | 2017 | 143 | 0.700 |
Why?
|
| Immunohistochemistry | 32 | 2018 | 7548 | 0.700 |
Why?
|
| Pinealoma | 6 | 2022 | 49 | 0.660 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2018 | 328 | 0.650 |
Why?
|
| Mitotic Index | 4 | 2014 | 162 | 0.640 |
Why?
|
| Neoplasm Grading | 12 | 2020 | 1742 | 0.640 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2019 | 534 | 0.640 |
Why?
|
| Oligodendroglioma | 11 | 2012 | 106 | 0.620 |
Why?
|
| Meningioma | 6 | 2017 | 289 | 0.620 |
Why?
|
| Brain | 25 | 2021 | 4113 | 0.610 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2019 | 673 | 0.580 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2018 | 280 | 0.580 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 182 | 0.580 |
Why?
|
| Glioma, Subependymal | 3 | 2023 | 25 | 0.570 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2021 | 716 | 0.560 |
Why?
|
| Meningeal Neoplasms | 5 | 2017 | 441 | 0.550 |
Why?
|
| Gene Duplication | 1 | 2018 | 421 | 0.540 |
Why?
|
| Medulloblastoma | 6 | 2020 | 540 | 0.540 |
Why?
|
| Rosette Formation | 1 | 2014 | 38 | 0.520 |
Why?
|
| Male | 99 | 2023 | 123000 | 0.510 |
Why?
|
| Repressor Proteins | 7 | 2019 | 1664 | 0.510 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 10 | 2006 | 2508 | 0.500 |
Why?
|
| Oncogenes | 5 | 2020 | 673 | 0.500 |
Why?
|
| Ependymoma | 3 | 2012 | 242 | 0.490 |
Why?
|
| Choroid Plexus Neoplasms | 2 | 2022 | 26 | 0.490 |
Why?
|
| Disease Progression | 23 | 2022 | 6682 | 0.480 |
Why?
|
| Middle Aged | 81 | 2023 | 86204 | 0.480 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2021 | 2359 | 0.480 |
Why?
|
| Diagnosis, Differential | 18 | 2021 | 4744 | 0.470 |
Why?
|
| Female | 106 | 2023 | 141928 | 0.470 |
Why?
|
| Adult | 75 | 2022 | 77950 | 0.470 |
Why?
|
| Chromosome Deletion | 3 | 2017 | 1005 | 0.460 |
Why?
|
| Neurocytoma | 3 | 2016 | 17 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2023 | 10035 | 0.450 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 4 | 2008 | 27 | 0.450 |
Why?
|
| Prognosis | 33 | 2022 | 21713 | 0.440 |
Why?
|
| MicroRNAs | 9 | 2017 | 2947 | 0.440 |
Why?
|
| Gliosarcoma | 4 | 2022 | 29 | 0.430 |
Why?
|
| Giant Cells | 1 | 2012 | 69 | 0.410 |
Why?
|
| Aged | 56 | 2021 | 70117 | 0.410 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 2283 | 0.410 |
Why?
|
| Mice | 59 | 2022 | 34495 | 0.410 |
Why?
|
| Cell Line, Tumor | 37 | 2022 | 14551 | 0.400 |
Why?
|
| Chordoma | 3 | 2018 | 163 | 0.400 |
Why?
|
| Adenoma | 4 | 2019 | 716 | 0.400 |
Why?
|
| Neuroimaging | 3 | 2019 | 403 | 0.400 |
Why?
|
| Endolymphatic Sac | 1 | 2010 | 11 | 0.390 |
Why?
|
| Tyrphostins | 6 | 2022 | 107 | 0.390 |
Why?
|
| Cell Proliferation | 23 | 2019 | 7226 | 0.380 |
Why?
|
| Ear Neoplasms | 1 | 2010 | 59 | 0.370 |
Why?
|
| Cell Adhesion Molecules | 5 | 2022 | 577 | 0.360 |
Why?
|
| Animals | 74 | 2022 | 59536 | 0.360 |
Why?
|
| Temporal Bone | 1 | 2010 | 102 | 0.350 |
Why?
|
| Pathology, Surgical | 2 | 2008 | 81 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-sis | 4 | 2014 | 80 | 0.350 |
Why?
|
| Neoplasms, Neuroepithelial | 3 | 2019 | 27 | 0.350 |
Why?
|
| Skull Base Neoplasms | 3 | 2018 | 314 | 0.350 |
Why?
|
| Ki-67 Antigen | 8 | 2019 | 666 | 0.340 |
Why?
|
| Point Mutation | 1 | 2012 | 769 | 0.340 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 134 | 0.340 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2019 | 63 | 0.330 |
Why?
|
| Brain Diseases | 3 | 2008 | 403 | 0.330 |
Why?
|
| Reference Books, Medical | 1 | 2008 | 4 | 0.330 |
Why?
|
| Neoplastic Stem Cells | 8 | 2019 | 1443 | 0.330 |
Why?
|
| Tissue Array Analysis | 11 | 2014 | 760 | 0.320 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2020 | 1048 | 0.320 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 621 | 0.310 |
Why?
|
| Spinal Cord Compression | 2 | 2021 | 151 | 0.310 |
Why?
|
| Tumor Microenvironment | 9 | 2022 | 2864 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2016 | 992 | 0.310 |
Why?
|
| Gene Expression Profiling | 12 | 2018 | 5159 | 0.310 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2007 | 53 | 0.300 |
Why?
|
| ErbB Receptors | 6 | 2015 | 2295 | 0.300 |
Why?
|
| Mice, Nude | 17 | 2021 | 4307 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 12 | 2019 | 3981 | 0.290 |
Why?
|
| Immunophenotyping | 2 | 2018 | 1681 | 0.290 |
Why?
|
| Third Ventricle | 1 | 2006 | 37 | 0.280 |
Why?
|
| Mice, Transgenic | 16 | 2020 | 4143 | 0.270 |
Why?
|
| Apoptosis | 14 | 2019 | 7591 | 0.270 |
Why?
|
| Neoplasm Proteins | 7 | 2018 | 3230 | 0.270 |
Why?
|
| Pyridines | 8 | 2022 | 1244 | 0.270 |
Why?
|
| Cell Cycle Proteins | 5 | 2017 | 2045 | 0.270 |
Why?
|
| Etoposide | 2 | 2022 | 870 | 0.260 |
Why?
|
| Carcinoma, Medullary | 1 | 2007 | 248 | 0.260 |
Why?
|
| Macrophages | 5 | 2022 | 1304 | 0.260 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2005 | 4 | 0.260 |
Why?
|
| Gene Fusion | 2 | 2020 | 209 | 0.260 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2017 | 202 | 0.250 |
Why?
|
| Forkhead Transcription Factors | 2 | 2009 | 778 | 0.250 |
Why?
|
| Spinal Cord Neoplasms | 3 | 2012 | 142 | 0.250 |
Why?
|
| Carcinoma | 6 | 2022 | 2578 | 0.250 |
Why?
|
| Child | 25 | 2020 | 29154 | 0.250 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5767 | 0.250 |
Why?
|
| Child, Preschool | 18 | 2020 | 16273 | 0.240 |
Why?
|
| Spinal Neoplasms | 2 | 2021 | 631 | 0.240 |
Why?
|
| Ganglioneuroma | 2 | 2020 | 41 | 0.240 |
Why?
|
| Genetic Markers | 3 | 2019 | 974 | 0.240 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2018 | 115 | 0.240 |
Why?
|
| Retrospective Studies | 31 | 2023 | 37905 | 0.240 |
Why?
|
| Young Adult | 23 | 2022 | 21445 | 0.240 |
Why?
|
| Encephalitis | 2 | 2021 | 143 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 9 | 2019 | 2054 | 0.240 |
Why?
|
| Fourth Ventricle | 3 | 2023 | 51 | 0.240 |
Why?
|
| Survival Rate | 20 | 2019 | 12221 | 0.230 |
Why?
|
| Hemangioma, Cavernous | 1 | 2023 | 27 | 0.230 |
Why?
|
| Cavernous Sinus | 1 | 2023 | 33 | 0.230 |
Why?
|
| Melanoma, Experimental | 3 | 2011 | 368 | 0.230 |
Why?
|
| Retinoblastoma | 4 | 2012 | 200 | 0.230 |
Why?
|
| Angiomatosis | 2 | 2016 | 26 | 0.230 |
Why?
|
| Disease Models, Animal | 15 | 2020 | 7222 | 0.230 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2003 | 72 | 0.230 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 29902 | 0.230 |
Why?
|
| Teratoma | 2 | 2015 | 236 | 0.230 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2003 | 100 | 0.220 |
Why?
|
| Adolescent | 28 | 2022 | 31252 | 0.220 |
Why?
|
| NF-kappa B | 3 | 2012 | 1549 | 0.220 |
Why?
|
| Neurons | 6 | 2018 | 2287 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 17 | 2020 | 6942 | 0.220 |
Why?
|
| Pituitary Gland | 3 | 2007 | 150 | 0.220 |
Why?
|
| Adenoviridae | 6 | 2018 | 1459 | 0.220 |
Why?
|
| Hemianopsia | 2 | 2021 | 42 | 0.220 |
Why?
|
| Melanoma | 8 | 2021 | 5317 | 0.210 |
Why?
|
| Gene Expression | 7 | 2018 | 3570 | 0.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2017 | 2232 | 0.210 |
Why?
|
| Microtomy | 1 | 2002 | 17 | 0.210 |
Why?
|
| Neuroma, Acoustic | 1 | 2022 | 55 | 0.210 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 1399 | 0.210 |
Why?
|
| Hemangioma | 1 | 2023 | 154 | 0.210 |
Why?
|
| RNA-Binding Proteins | 2 | 2019 | 984 | 0.210 |
Why?
|
| Visual Fields | 2 | 2021 | 142 | 0.200 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 15694 | 0.200 |
Why?
|
| Granuloma, Plasma Cell | 2 | 2016 | 38 | 0.200 |
Why?
|
| Monocytes | 3 | 2014 | 788 | 0.200 |
Why?
|
| Eye Neoplasms | 3 | 2009 | 247 | 0.200 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2021 | 30 | 0.200 |
Why?
|
| Staining and Labeling | 2 | 2003 | 429 | 0.200 |
Why?
|
| Paraffin Embedding | 1 | 2002 | 226 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2018 | 1248 | 0.200 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2021 | 31 | 0.200 |
Why?
|
| Cohort Studies | 11 | 2020 | 9244 | 0.190 |
Why?
|
| Central Nervous System Diseases | 1 | 2002 | 129 | 0.190 |
Why?
|
| Ocular Motility Disorders | 1 | 2021 | 47 | 0.190 |
Why?
|
| Thyroid Neoplasms | 2 | 2013 | 1866 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2017 | 6207 | 0.190 |
Why?
|
| Cell Movement | 6 | 2016 | 2466 | 0.190 |
Why?
|
| Transcriptome | 4 | 2020 | 1859 | 0.190 |
Why?
|
| Bevacizumab | 5 | 2016 | 938 | 0.190 |
Why?
|
| Immune Tolerance | 3 | 2013 | 403 | 0.190 |
Why?
|
| Algorithms | 6 | 2015 | 3890 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2011 | 528 | 0.180 |
Why?
|
| Nervous System Neoplasms | 2 | 2014 | 36 | 0.180 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2020 | 51 | 0.180 |
Why?
|
| DNA-Binding Proteins | 5 | 2006 | 4821 | 0.180 |
Why?
|
| Genes, erbB-2 | 1 | 2020 | 229 | 0.180 |
Why?
|
| Dexamethasone | 2 | 2018 | 1450 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2018 | 7551 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 201 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 551 | 0.170 |
Why?
|
| Ameloblastoma | 1 | 2019 | 17 | 0.170 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 14289 | 0.170 |
Why?
|
| Flow Cytometry | 8 | 2015 | 3033 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 117 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 2 | 2016 | 821 | 0.170 |
Why?
|
| Integrin beta1 | 2 | 2012 | 126 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 2326 | 0.170 |
Why?
|
| S100 Proteins | 3 | 2015 | 181 | 0.170 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2015 | 151 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2016 | 1022 | 0.170 |
Why?
|
| Histiocytosis, Sinus | 2 | 2011 | 86 | 0.170 |
Why?
|
| Radiosurgery | 2 | 2018 | 1330 | 0.170 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2019 | 113 | 0.170 |
Why?
|
| Receptors, Cell Surface | 4 | 2016 | 862 | 0.170 |
Why?
|
| Meninges | 2 | 2016 | 47 | 0.160 |
Why?
|
| Astrocytes | 3 | 2018 | 368 | 0.160 |
Why?
|
| T-Lymphocytes | 7 | 2020 | 3869 | 0.160 |
Why?
|
| DNA Repair | 2 | 2018 | 1872 | 0.160 |
Why?
|
| Anaplasia | 1 | 2018 | 18 | 0.160 |
Why?
|
| Transcription Factors | 5 | 2016 | 5270 | 0.160 |
Why?
|
| Mandibular Neoplasms | 1 | 2019 | 76 | 0.160 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2018 | 73 | 0.160 |
Why?
|
| Neural Stem Cells | 2 | 2016 | 181 | 0.160 |
Why?
|
| Signal Transduction | 20 | 2020 | 11965 | 0.160 |
Why?
|
| Brain Abscess | 2 | 2012 | 60 | 0.160 |
Why?
|
| Corpus Striatum | 1 | 2018 | 104 | 0.160 |
Why?
|
| Treatment Outcome | 20 | 2022 | 32848 | 0.160 |
Why?
|
| Osteopontin | 1 | 2018 | 148 | 0.160 |
Why?
|
| Locomotion | 1 | 2018 | 84 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 1586 | 0.160 |
Why?
|
| Paraproteinemias | 1 | 2018 | 61 | 0.160 |
Why?
|
| Fibrinogen | 1 | 2019 | 205 | 0.160 |
Why?
|
| Follow-Up Studies | 11 | 2020 | 14889 | 0.160 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 301 | 0.160 |
Why?
|
| F-Box Proteins | 1 | 2018 | 96 | 0.160 |
Why?
|
| Immunity, Innate | 2 | 2020 | 677 | 0.160 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 43 | 0.150 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2015 | 123 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 11 | 2019 | 5395 | 0.150 |
Why?
|
| Research Design | 2 | 2002 | 1544 | 0.150 |
Why?
|
| Wnt Proteins | 1 | 2019 | 397 | 0.150 |
Why?
|
| Mad2 Proteins | 1 | 2017 | 33 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 4 | 2019 | 3101 | 0.150 |
Why?
|
| Cell Communication | 1 | 2020 | 509 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 1547 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2016 | 476 | 0.150 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2017 | 61 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 4892 | 0.150 |
Why?
|
| Wnt-5a Protein | 1 | 2016 | 45 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2005 | 2488 | 0.140 |
Why?
|
| Cdc20 Proteins | 1 | 2016 | 25 | 0.140 |
Why?
|
| Transcription, Genetic | 6 | 2019 | 3154 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 1064 | 0.140 |
Why?
|
| Molecular Imaging | 1 | 2018 | 185 | 0.140 |
Why?
|
| RNA, Small Interfering | 4 | 2012 | 2216 | 0.140 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 327 | 0.140 |
Why?
|
| Skull Base | 1 | 2017 | 199 | 0.140 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 90 | 0.140 |
Why?
|
| Endosomes | 1 | 2016 | 109 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 462 | 0.140 |
Why?
|
| Hydroxamic Acids | 2 | 2011 | 442 | 0.140 |
Why?
|
| Neurosurgical Procedures | 3 | 2021 | 609 | 0.140 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2016 | 113 | 0.140 |
Why?
|
| Genes, p53 | 2 | 2015 | 1090 | 0.140 |
Why?
|
| Phosphorylation | 9 | 2014 | 4804 | 0.140 |
Why?
|
| Scalp | 1 | 2017 | 156 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 701 | 0.130 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2016 | 195 | 0.130 |
Why?
|
| Oncolytic Viruses | 1 | 2018 | 204 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 7 | 2016 | 2314 | 0.130 |
Why?
|
| Laminectomy | 1 | 2015 | 52 | 0.130 |
Why?
|
| Carrier Proteins | 4 | 2010 | 2022 | 0.130 |
Why?
|
| Neuroglia | 2 | 2007 | 223 | 0.130 |
Why?
|
| Cell Differentiation | 7 | 2016 | 4078 | 0.130 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 2 | 2006 | 36 | 0.130 |
Why?
|
| Cervical Cord | 1 | 2015 | 19 | 0.130 |
Why?
|
| Radiation Injuries | 4 | 2016 | 1411 | 0.130 |
Why?
|
| Skin Neoplasms | 4 | 2017 | 4654 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 1 | 2018 | 280 | 0.130 |
Why?
|
| Animals, Newborn | 7 | 2016 | 1338 | 0.130 |
Why?
|
| Diagnostic Errors | 4 | 2010 | 509 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2019 | 3821 | 0.130 |
Why?
|
| Phenotype | 5 | 2022 | 6295 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 2594 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2005 | 479 | 0.120 |
Why?
|
| Genetic Therapy | 3 | 2012 | 1616 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2016 | 649 | 0.120 |
Why?
|
| Steroids | 1 | 2016 | 356 | 0.120 |
Why?
|
| Separase | 1 | 2014 | 32 | 0.120 |
Why?
|
| Mucorales | 1 | 2014 | 31 | 0.120 |
Why?
|
| Myelin Sheath | 3 | 1984 | 149 | 0.120 |
Why?
|
| Cells, Cultured | 7 | 2020 | 5637 | 0.120 |
Why?
|
| Lysosomes | 1 | 2016 | 347 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1375 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2014 | 110 | 0.120 |
Why?
|
| Carcinoma, Papillary | 2 | 2015 | 584 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 651 | 0.120 |
Why?
|
| Genetic Vectors | 5 | 2012 | 1694 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2014 | 332 | 0.120 |
Why?
|
| Nutrition Disorders | 5 | 1984 | 57 | 0.120 |
Why?
|
| Neoplasm Transplantation | 5 | 2013 | 1519 | 0.120 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 214 | 0.120 |
Why?
|
| Protein Kinases | 2 | 2016 | 874 | 0.120 |
Why?
|
| Cell Adhesion | 2 | 2006 | 1008 | 0.120 |
Why?
|
| Methotrexate | 1 | 2017 | 999 | 0.120 |
Why?
|
| Microarray Analysis | 3 | 2009 | 392 | 0.110 |
Why?
|
| Aspergillus | 1 | 2014 | 149 | 0.110 |
Why?
|
| RNA Interference | 4 | 2013 | 1408 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.110 |
Why?
|
| Fatal Outcome | 7 | 2015 | 829 | 0.110 |
Why?
|
| Biopsy | 2 | 2018 | 3443 | 0.110 |
Why?
|
| Lymphatic Metastasis | 4 | 2009 | 4844 | 0.110 |
Why?
|
| Ovarian Neoplasms | 3 | 2016 | 4638 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1350 | 0.110 |
Why?
|
| Mucormycosis | 1 | 2014 | 108 | 0.110 |
Why?
|
| Mitosporic Fungi | 1 | 2012 | 15 | 0.110 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 10001 | 0.110 |
Why?
|
| Protein Array Analysis | 3 | 2006 | 501 | 0.110 |
Why?
|
| Cadherins | 1 | 2016 | 660 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 566 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2018 | 4367 | 0.110 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 1910 | 0.110 |
Why?
|
| Chromatin | 1 | 2018 | 942 | 0.110 |
Why?
|
| Vertigo | 2 | 2010 | 47 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2014 | 2450 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.110 |
Why?
|
| Blotting, Western | 7 | 2016 | 3536 | 0.110 |
Why?
|
| Coinfection | 1 | 2014 | 189 | 0.110 |
Why?
|
| Aspergillosis | 1 | 2014 | 246 | 0.110 |
Why?
|
| Infratentorial Neoplasms | 1 | 2012 | 45 | 0.110 |
Why?
|
| Pyrimidines | 3 | 2018 | 3518 | 0.100 |
Why?
|
| Cerebrum | 1 | 2012 | 44 | 0.100 |
Why?
|
| Injections, Spinal | 2 | 2017 | 257 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2015 | 731 | 0.100 |
Why?
|
| Stem Cells | 3 | 2016 | 1213 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 1 | 2015 | 341 | 0.100 |
Why?
|
| Sarcoma | 2 | 2016 | 1725 | 0.100 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 657 | 0.100 |
Why?
|
| Molecular Biology | 1 | 2012 | 176 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 854 | 0.100 |
Why?
|
| Cyclin B1 | 1 | 2011 | 56 | 0.100 |
Why?
|
| Receptor, TIE-2 | 2 | 2014 | 82 | 0.100 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 2 | 2003 | 110 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 810 | 0.100 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2011 | 42 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 895 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 987 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 5 | 2012 | 1491 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.100 |
Why?
|
| GATA4 Transcription Factor | 1 | 2011 | 45 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2011 | 1823 | 0.100 |
Why?
|
| Spinal Diseases | 2 | 2011 | 125 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2014 | 1620 | 0.100 |
Why?
|
| DNA Methylation | 4 | 2018 | 2669 | 0.100 |
Why?
|
| Oligopeptides | 2 | 2010 | 429 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 4 | 2018 | 1077 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 15862 | 0.100 |
Why?
|
| G2 Phase | 1 | 2011 | 206 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 5 | 2015 | 1165 | 0.100 |
Why?
|
| Integrin alphaV | 1 | 2010 | 20 | 0.090 |
Why?
|
| Time Factors | 10 | 2019 | 12926 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 709 | 0.090 |
Why?
|
| Tinnitus | 1 | 2010 | 38 | 0.090 |
Why?
|
| Myoblasts | 1 | 2010 | 72 | 0.090 |
Why?
|
| Genome, Human | 2 | 2019 | 1869 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 1215 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1763 | 0.090 |
Why?
|
| Nose Neoplasms | 2 | 2003 | 229 | 0.090 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 8865 | 0.090 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 3022 | 0.090 |
Why?
|
| Cerebral Ventricles | 1 | 2010 | 98 | 0.090 |
Why?
|
| Cell Lineage | 3 | 2008 | 668 | 0.090 |
Why?
|
| Cell Cycle | 5 | 2017 | 2084 | 0.090 |
Why?
|
| Gene Deletion | 3 | 2011 | 1442 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2011 | 612 | 0.090 |
Why?
|
| Genes, Neoplasm | 2 | 2018 | 324 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2005 | 600 | 0.090 |
Why?
|
| Enzyme Activation | 4 | 2008 | 1764 | 0.090 |
Why?
|
| Choroid Neoplasms | 1 | 2009 | 41 | 0.090 |
Why?
|
| Receptors, Somatostatin | 1 | 2009 | 85 | 0.090 |
Why?
|
| Terminology as Topic | 2 | 2020 | 414 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2018 | 1823 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2016 | 882 | 0.090 |
Why?
|
| Hearing Loss | 1 | 2010 | 153 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2014 | 1062 | 0.090 |
Why?
|
| Integrin alpha6beta4 | 1 | 2009 | 31 | 0.090 |
Why?
|
| Wernicke Encephalopathy | 1 | 2008 | 12 | 0.080 |
Why?
|
| SOX9 Transcription Factor | 1 | 2010 | 170 | 0.080 |
Why?
|
| Chickens | 4 | 2012 | 523 | 0.080 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 60 | 0.080 |
Why?
|
| Vincristine | 3 | 2022 | 1511 | 0.080 |
Why?
|
| Mycoses | 1 | 2012 | 386 | 0.080 |
Why?
|
| Cerebellum | 2 | 2010 | 449 | 0.080 |
Why?
|
| Mice, Knockout | 5 | 2018 | 5710 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2009 | 582 | 0.080 |
Why?
|
| Tretinoin | 1 | 2011 | 623 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 1756 | 0.080 |
Why?
|
| Halothane | 2 | 1985 | 21 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2020 | 3251 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 205 | 0.080 |
Why?
|
| Leukemia | 1 | 2017 | 1635 | 0.080 |
Why?
|
| Melanins | 1 | 2008 | 50 | 0.080 |
Why?
|
| Hypoxia | 1 | 2011 | 443 | 0.080 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2007 | 7 | 0.080 |
Why?
|
| Dogs | 1 | 2009 | 1155 | 0.080 |
Why?
|
| Proton Therapy | 1 | 2018 | 1577 | 0.080 |
Why?
|
| Germinoma | 1 | 2008 | 84 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 3 | 2010 | 545 | 0.080 |
Why?
|
| Receptors, AMPA | 1 | 2008 | 70 | 0.080 |
Why?
|
| Vision, Low | 1 | 2007 | 18 | 0.080 |
Why?
|
| Base Sequence | 6 | 2013 | 4917 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2016 | 986 | 0.080 |
Why?
|
| Optic Chiasm | 2 | 2004 | 40 | 0.080 |
Why?
|
| Iron | 1 | 2010 | 376 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 365 | 0.080 |
Why?
|
| Conjunctiva | 1 | 2009 | 250 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2015 | 5178 | 0.070 |
Why?
|
| Loss of Heterozygosity | 2 | 2005 | 602 | 0.070 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 354 | 0.070 |
Why?
|
| RNA, Messenger | 7 | 2015 | 6150 | 0.070 |
Why?
|
| Cell Count | 2 | 2005 | 508 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2015 | 2054 | 0.070 |
Why?
|
| Integrin alpha5 | 1 | 2006 | 15 | 0.070 |
Why?
|
| Spinal Puncture | 1 | 2006 | 63 | 0.070 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2006 | 57 | 0.070 |
Why?
|
| Median Neuropathy | 1 | 2006 | 4 | 0.070 |
Why?
|
| Angiopoietin-2 | 1 | 2006 | 38 | 0.070 |
Why?
|
| Neoplasm Staging | 10 | 2015 | 13658 | 0.070 |
Why?
|
| Myelin Proteins | 3 | 1981 | 90 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 2013 | 6089 | 0.070 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2004 | 243 | 0.070 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 11538 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 200 | 0.070 |
Why?
|
| Lipomatosis | 1 | 2006 | 24 | 0.070 |
Why?
|
| E2F1 Transcription Factor | 1 | 2007 | 206 | 0.070 |
Why?
|
| Narcotics | 1 | 2006 | 123 | 0.070 |
Why?
|
| Paraganglioma | 1 | 2008 | 170 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 153 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2010 | 889 | 0.070 |
Why?
|
| Deoxyribonucleases | 1 | 2005 | 46 | 0.070 |
Why?
|
| Radiotherapy | 3 | 2018 | 1824 | 0.070 |
Why?
|
| Proportional Hazards Models | 6 | 2015 | 4988 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2011 | 686 | 0.070 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2005 | 27 | 0.070 |
Why?
|
| Alternative Splicing | 2 | 2005 | 584 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2012 | 3639 | 0.060 |
Why?
|
| Fingers | 1 | 2006 | 120 | 0.060 |
Why?
|
| RNA Splice Sites | 1 | 2005 | 111 | 0.060 |
Why?
|
| Vascular Neoplasms | 1 | 2006 | 114 | 0.060 |
Why?
|
| Vimentin | 1 | 2006 | 253 | 0.060 |
Why?
|
| Muscle Weakness | 1 | 2006 | 116 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 4 | 2010 | 256 | 0.060 |
Why?
|
| Hamartoma | 1 | 2006 | 115 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2014 | 1533 | 0.060 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2005 | 84 | 0.060 |
Why?
|
| Receptor, Notch1 | 1 | 2006 | 218 | 0.060 |
Why?
|
| DNA Helicases | 2 | 2019 | 434 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 592 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 4053 | 0.060 |
Why?
|
| Embryo, Mammalian | 2 | 2018 | 741 | 0.060 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2008 | 261 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 461 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 1217 | 0.060 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2004 | 19 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1493 | 0.060 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2004 | 36 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2004 | 101 | 0.060 |
Why?
|
| Down-Regulation | 4 | 2014 | 2074 | 0.060 |
Why?
|
| ras Proteins | 4 | 2016 | 770 | 0.060 |
Why?
|
| Radiography | 3 | 2022 | 1904 | 0.060 |
Why?
|
| Nasal Cavity | 2 | 2003 | 149 | 0.060 |
Why?
|
| Genes, myc | 1 | 2006 | 358 | 0.060 |
Why?
|
| Hemostasis, Surgical | 1 | 2004 | 48 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2010 | 5112 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3001 | 0.060 |
Why?
|
| Parotid Neoplasms | 1 | 2005 | 148 | 0.060 |
Why?
|
| Rats | 13 | 2006 | 6086 | 0.060 |
Why?
|
| Cysts | 1 | 2005 | 197 | 0.060 |
Why?
|
| Melanocytes | 2 | 2021 | 219 | 0.060 |
Why?
|
| Sciatic Nerve | 2 | 1981 | 112 | 0.060 |
Why?
|
| Survival Analysis | 6 | 2015 | 9180 | 0.060 |
Why?
|
| Fusobacterium Infections | 1 | 2003 | 28 | 0.060 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2003 | 19 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2014 | 6869 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 2576 | 0.060 |
Why?
|
| Heterografts | 2 | 2016 | 733 | 0.060 |
Why?
|
| Genetic Heterogeneity | 1 | 2005 | 318 | 0.060 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2003 | 50 | 0.060 |
Why?
|
| Multigene Family | 1 | 2005 | 425 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 639 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5539 | 0.060 |
Why?
|
| Septum Pellucidum | 1 | 2003 | 11 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 554 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2018 | 3552 | 0.060 |
Why?
|
| Hydrocephalus | 2 | 2021 | 217 | 0.060 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1984 | 73 | 0.060 |
Why?
|
| Agglutinins | 1 | 2002 | 19 | 0.060 |
Why?
|
| Meningeal Arteries | 1 | 2002 | 9 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.060 |
Why?
|
| Nevus, Pigmented | 1 | 2003 | 104 | 0.060 |
Why?
|
| Mucoproteins | 1 | 2022 | 25 | 0.060 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2022 | 30 | 0.060 |
Why?
|
| Neutrophil Infiltration | 2 | 2013 | 109 | 0.060 |
Why?
|
| Telomerase | 1 | 2006 | 525 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 694 | 0.050 |
Why?
|
| Infant | 5 | 2019 | 13310 | 0.050 |
Why?
|
| Nestin | 2 | 2012 | 42 | 0.050 |
Why?
|
| Uveal Neoplasms | 1 | 2004 | 176 | 0.050 |
Why?
|
| Sacrococcygeal Region | 1 | 2002 | 37 | 0.050 |
Why?
|
| Dura Mater | 1 | 2002 | 73 | 0.050 |
Why?
|
| Intermediate Filament Proteins | 2 | 2012 | 81 | 0.050 |
Why?
|
| Transfection | 4 | 2010 | 2944 | 0.050 |
Why?
|
| Orbital Neoplasms | 1 | 2004 | 224 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 1879 | 0.050 |
Why?
|
| Chorea | 1 | 2002 | 34 | 0.050 |
Why?
|
| Injections, Intralesional | 2 | 2018 | 164 | 0.050 |
Why?
|
| Caffeine | 1 | 1982 | 87 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2016 | 1869 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 43 | 0.050 |
Why?
|
| West Nile virus | 1 | 2003 | 128 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 499 | 0.050 |
Why?
|
| Avian Proteins | 2 | 2012 | 27 | 0.050 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2002 | 82 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2011 | 2967 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2004 | 370 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 343 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 2231 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2015 | 1053 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 252 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 624 | 0.050 |
Why?
|
| Genes, p16 | 1 | 2002 | 125 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2003 | 269 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2002 | 185 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 1265 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2003 | 151 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 2010 | 1506 | 0.050 |
Why?
|
| Pupil Disorders | 1 | 2021 | 22 | 0.050 |
Why?
|
| Nystagmus, Pathologic | 1 | 2021 | 43 | 0.050 |
Why?
|
| Doxycycline | 2 | 2016 | 178 | 0.050 |
Why?
|
| Lasers | 1 | 2002 | 198 | 0.050 |
Why?
|
| Receptors, Virus | 2 | 2012 | 157 | 0.050 |
Why?
|
| Dacarbazine | 2 | 2015 | 485 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 143 | 0.050 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2003 | 192 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2003 | 388 | 0.050 |
Why?
|
| Polyradiculopathy | 1 | 2000 | 13 | 0.050 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2020 | 27 | 0.050 |
Why?
|
| Cyclin D1 | 2 | 2014 | 576 | 0.050 |
Why?
|
| Apyrase | 1 | 2020 | 44 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 61 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 543 | 0.050 |
Why?
|
| RNA, Neoplasm | 3 | 2013 | 771 | 0.050 |
Why?
|
| DNA Demethylation | 1 | 2019 | 10 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2020 | 148 | 0.050 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 36 | 0.050 |
Why?
|
| Tumor Escape | 2 | 2013 | 251 | 0.050 |
Why?
|
| Chitinase-3-Like Protein 1 | 2 | 2012 | 18 | 0.040 |
Why?
|
| Tubulin | 2 | 2010 | 169 | 0.040 |
Why?
|
| Models, Animal | 2 | 2018 | 664 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 1 | 2002 | 408 | 0.040 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 144 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2022 | 436 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2020 | 1385 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2011 | 448 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 3203 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2019 | 44 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2018 | 929 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2020 | 272 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 3719 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2009 | 2518 | 0.040 |
Why?
|
| Lectins | 2 | 2012 | 151 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2000 | 112 | 0.040 |
Why?
|
| Acetylation | 2 | 2011 | 508 | 0.040 |
Why?
|
| Receptors, Vitronectin | 1 | 2018 | 24 | 0.040 |
Why?
|
| Genomics | 2 | 2018 | 2738 | 0.040 |
Why?
|
| Adipokines | 2 | 2012 | 96 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 264 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2004 | 1152 | 0.040 |
Why?
|
| Cytokines | 3 | 2014 | 2809 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 370 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 500 | 0.040 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2018 | 19 | 0.040 |
Why?
|
| Aptamers, Nucleotide | 1 | 2018 | 62 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 201 | 0.040 |
Why?
|
| Creatine | 1 | 2018 | 61 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2017 | 1682 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 4938 | 0.040 |
Why?
|
| Incidence | 1 | 2008 | 5673 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2018 | 171 | 0.040 |
Why?
|
| Choline | 1 | 2018 | 76 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Protein Binding | 3 | 2010 | 3438 | 0.040 |
Why?
|
| Organ Size | 3 | 1984 | 690 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2014 | 842 | 0.040 |
Why?
|
| Risk | 2 | 2015 | 1972 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2015 | 2218 | 0.040 |
Why?
|
| Carcinogenicity Tests | 2 | 2008 | 70 | 0.040 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2017 | 18 | 0.040 |
Why?
|
| Antifungal Agents | 2 | 2014 | 834 | 0.040 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 1013 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 2012 | 328 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 1678 | 0.040 |
Why?
|
| Necrosis | 3 | 2004 | 580 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 1487 | 0.040 |
Why?
|
| PAX6 Transcription Factor | 1 | 2016 | 53 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 482 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 575 | 0.040 |
Why?
|
| Exons | 3 | 2005 | 1328 | 0.040 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2009 | 189 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 430 | 0.040 |
Why?
|
| Stroke | 1 | 2005 | 1144 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 973 | 0.040 |
Why?
|
| Homeodomain Proteins | 2 | 2016 | 1143 | 0.040 |
Why?
|
| Indazoles | 1 | 2018 | 297 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2006 | 1371 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 419 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2013 | 837 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 1648 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2000 | 393 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 1082 | 0.040 |
Why?
|
| Homocysteine | 1 | 2017 | 138 | 0.040 |
Why?
|
| Machine Learning | 1 | 2019 | 319 | 0.040 |
Why?
|
| Cell Line | 3 | 2011 | 5114 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2017 | 233 | 0.030 |
Why?
|
| Rare Diseases | 2 | 2011 | 351 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 94 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2017 | 369 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2022 | 1987 | 0.030 |
Why?
|
| Headache | 2 | 2008 | 163 | 0.030 |
Why?
|
| Models, Biological | 1 | 2005 | 3254 | 0.030 |
Why?
|
| beta Catenin | 1 | 2019 | 688 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 187 | 0.030 |
Why?
|
| Mitosis | 1 | 2018 | 615 | 0.030 |
Why?
|
| Piperazines | 1 | 2004 | 2101 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2011 | 589 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2016 | 186 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 1914 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2006 | 2819 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 266 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 205 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2014 | 84 | 0.030 |
Why?
|
| Image Enhancement | 2 | 2010 | 561 | 0.030 |
Why?
|
| Extremities | 1 | 2016 | 303 | 0.030 |
Why?
|
| Texas | 2 | 2018 | 6311 | 0.030 |
Why?
|
| Proteolysis | 1 | 2016 | 370 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 507 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 249 | 0.030 |
Why?
|
| Mannans | 1 | 2014 | 31 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2004 | 6100 | 0.030 |
Why?
|
| Galactose | 1 | 2014 | 87 | 0.030 |
Why?
|
| Computational Biology | 2 | 2016 | 1271 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 349 | 0.030 |
Why?
|
| Registries | 1 | 2022 | 2170 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2020 | 1085 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2014 | 196 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 905 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2013 | 57 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2018 | 873 | 0.030 |
Why?
|
| Aurora Kinase A | 1 | 2014 | 202 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 4758 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2009 | 1363 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 519 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2014 | 129 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 241 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 292 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2013 | 108 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 360 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2015 | 614 | 0.030 |
Why?
|
| Genes, sis | 1 | 2012 | 2 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2012 | 26 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2005 | 2341 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2014 | 333 | 0.030 |
Why?
|
| Cell Survival | 2 | 2010 | 3045 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 157 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2013 | 201 | 0.030 |
Why?
|
| Microglia | 1 | 2013 | 164 | 0.030 |
Why?
|
| Spleen | 1 | 2014 | 676 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2012 | 136 | 0.030 |
Why?
|
| Administration, Metronomic | 1 | 2011 | 15 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 541 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 1283 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 663 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1618 | 0.030 |
Why?
|
| Avian Leukosis Virus | 1 | 2011 | 12 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 170 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 629 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 6009 | 0.020 |
Why?
|
| Neurosurgery | 1 | 2012 | 108 | 0.020 |
Why?
|
| Salivary Gland Diseases | 1 | 2011 | 10 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2010 | 4233 | 0.020 |
Why?
|
| Benzamides | 2 | 2009 | 1832 | 0.020 |
Why?
|
| Retroviridae | 1 | 2012 | 332 | 0.020 |
Why?
|
| Positron-Emission Tomography | 2 | 2011 | 2173 | 0.020 |
Why?
|
| Pituitary Diseases | 1 | 2011 | 18 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 222 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2010 | 45 | 0.020 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2011 | 26 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 2011 | 53 | 0.020 |
Why?
|
| Contactin 2 | 1 | 2010 | 8 | 0.020 |
Why?
|
| Transferrin | 1 | 2010 | 78 | 0.020 |
Why?
|
| Stathmin | 1 | 2010 | 30 | 0.020 |
Why?
|
| Stromal Cells | 2 | 2005 | 825 | 0.020 |
Why?
|
| Drosophila | 1 | 2016 | 839 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 1555 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 553 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2010 | 72 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 4971 | 0.020 |
Why?
|
| Mediastinal Diseases | 1 | 2011 | 56 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2011 | 172 | 0.020 |
Why?
|
| Neurofilament Proteins | 1 | 2010 | 30 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 241 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2016 | 1048 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 154 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2010 | 105 | 0.020 |
Why?
|
| Peptide Library | 1 | 2010 | 158 | 0.020 |
Why?
|
| Cyanoacrylates | 1 | 2010 | 41 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2010 | 166 | 0.020 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2010 | 82 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1945 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2009 | 105 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 1129 | 0.020 |
Why?
|
| Histone Deacetylase 6 | 1 | 2009 | 44 | 0.020 |
Why?
|
| Body Weight | 3 | 1984 | 1293 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 237 | 0.020 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2011 | 137 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2009 | 156 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 238 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 25 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 1216 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 503 | 0.020 |
Why?
|
| Confusion | 1 | 2008 | 31 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 376 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2009 | 3005 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2171 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 633 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2009 | 303 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2009 | 145 | 0.020 |
Why?
|
| Survivors | 1 | 2014 | 1031 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 359 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 518 | 0.020 |
Why?
|
| Evoked Potentials, Auditory | 2 | 1985 | 50 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 886 | 0.020 |
Why?
|
| RNA, Double-Stranded | 1 | 2008 | 79 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 460 | 0.020 |
Why?
|
| Animals, Suckling | 2 | 1984 | 54 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 675 | 0.020 |
Why?
|
| Sella Turcica | 1 | 2007 | 24 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2011 | 349 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 803 | 0.020 |
Why?
|
| Topotecan | 1 | 2008 | 239 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2008 | 344 | 0.020 |
Why?
|
| Retina | 2 | 1982 | 532 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2007 | 42 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 755 | 0.020 |
Why?
|
| Quinazolines | 1 | 2012 | 923 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 591 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2483 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2007 | 78 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 4298 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 2008 | 223 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 394 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 1954 | 0.020 |
Why?
|
| Subarachnoid Space | 1 | 2006 | 36 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1313 | 0.020 |
Why?
|
| Transcription Factor HES-1 | 1 | 2006 | 49 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2009 | 696 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2016 | 1249 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2014 | 2358 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2006 | 114 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 189 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2008 | 192 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 131 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 598 | 0.020 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2005 | 7 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1732 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 1688 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1985 | 410 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 667 | 0.020 |
Why?
|
| Neuronavigation | 1 | 2005 | 47 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 726 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 143 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 1985 | 118 | 0.020 |
Why?
|
| Microcirculation | 1 | 2006 | 200 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 6550 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2005 | 109 | 0.020 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 81 | 0.020 |
Why?
|
| Food Deprivation | 2 | 1984 | 47 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2007 | 183 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2006 | 178 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 57 | 0.020 |
Why?
|
| Carboplatin | 1 | 2008 | 823 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2005 | 72 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 55 | 0.020 |
Why?
|
| Transcription Factor AP-2 | 1 | 2005 | 79 | 0.020 |
Why?
|
| Cotton Fiber | 1 | 2004 | 8 | 0.020 |
Why?
|
| Cellulose, Oxidized | 1 | 2004 | 6 | 0.020 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2004 | 9 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 2005 | 89 | 0.020 |
Why?
|
| United States | 1 | 2022 | 15433 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2010 | 904 | 0.020 |
Why?
|
| Visual Field Tests | 1 | 2004 | 50 | 0.020 |
Why?
|
| Morphine | 1 | 2006 | 308 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2005 | 157 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2005 | 220 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2009 | 779 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1033 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 259 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2006 | 575 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 545 | 0.020 |
Why?
|
| Peptostreptococcus | 1 | 2003 | 7 | 0.020 |
Why?
|
| Bacteroides Infections | 1 | 2003 | 10 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 392 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3343 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4320 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1984 | 159 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 471 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 280 | 0.010 |
Why?
|
| Hemostatics | 1 | 2004 | 88 | 0.010 |
Why?
|
| Hippocalcin | 1 | 2003 | 13 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2012 | 1471 | 0.010 |
Why?
|
| Trypan Blue | 1 | 2003 | 14 | 0.010 |
Why?
|
| Recoverin | 1 | 2003 | 22 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 1226 | 0.010 |
Why?
|
| Craniotomy | 1 | 2005 | 304 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2018 | 12873 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 869 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2004 | 193 | 0.010 |
Why?
|
| Optic Nerve | 1 | 1984 | 133 | 0.010 |
Why?
|
| Risk Factors | 2 | 2012 | 17523 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 324 | 0.010 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 323 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 221 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 3151 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2005 | 344 | 0.010 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2002 | 11 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 2049 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 837 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 652 | 0.010 |
Why?
|
| Geniculate Bodies | 1 | 1982 | 23 | 0.010 |
Why?
|
| Gait Apraxia | 1 | 2002 | 1 | 0.010 |
Why?
|
| Evoked Potentials, Visual | 1 | 1982 | 39 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 1391 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2006 | 690 | 0.010 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2002 | 41 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2004 | 447 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2006 | 436 | 0.010 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2002 | 20 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 747 | 0.010 |
Why?
|
| Ethmoid Sinus | 1 | 2002 | 27 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 234 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 850 | 0.010 |
Why?
|
| Sphenoid Sinus | 1 | 2002 | 21 | 0.010 |
Why?
|
| Mastectomy | 1 | 2009 | 1534 | 0.010 |
Why?
|
| Case Management | 1 | 2002 | 35 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 15193 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 622 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2002 | 425 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 661 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2003 | 157 | 0.010 |
Why?
|
| Hypopituitarism | 1 | 2002 | 33 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 475 | 0.010 |
Why?
|
| Biomarkers | 1 | 2013 | 5047 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2002 | 132 | 0.010 |
Why?
|
| Blindness | 1 | 2002 | 77 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3569 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2006 | 486 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2002 | 107 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 2063 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 690 | 0.010 |
Why?
|
| Veins | 1 | 2002 | 157 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 756 | 0.010 |
Why?
|
| Integrins | 1 | 2003 | 262 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 891 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 295 | 0.010 |
Why?
|
| Adrenergic Fibers | 1 | 1981 | 8 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 2055 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2002 | 159 | 0.010 |
Why?
|
| Limbic System | 1 | 1981 | 29 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 2002 | 183 | 0.010 |
Why?
|
| Purkinje Cells | 1 | 2002 | 143 | 0.010 |
Why?
|
| Contrast Media | 1 | 2008 | 1472 | 0.010 |
Why?
|
| Visual Cortex | 1 | 1982 | 136 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 3890 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 752 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 848 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 1070 | 0.010 |
Why?
|
| Genes | 1 | 2002 | 491 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 459 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 292 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 1099 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 1152 | 0.010 |
Why?
|
| Nerve Regeneration | 1 | 1981 | 105 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2002 | 335 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 2588 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 2927 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 1665 | 0.010 |
Why?
|
| Clostridium Infections | 1 | 2003 | 252 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 665 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2002 | 604 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2006 | 1546 | 0.010 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2002 | 285 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2002 | 745 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2005 | 1331 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 3441 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 2437 | 0.010 |
Why?
|
| Pain | 1 | 2006 | 1658 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 4109 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2006 | 2086 | 0.010 |
Why?
|
| Leucine | 1 | 1979 | 352 | 0.010 |
Why?
|
| Lipids | 1 | 1981 | 644 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 2138 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 1538 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 2522 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 2432 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 4757 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 5377 | 0.010 |
Why?
|
| Norepinephrine | 2 | 1984 | 272 | 0.010 |
Why?
|
| Quality of Life | 1 | 2006 | 4532 | 0.010 |
Why?
|
| Dopamine | 2 | 1984 | 312 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2008 | 6915 | 0.010 |
Why?
|
| Choline O-Acetyltransferase | 1 | 1984 | 19 | 0.000 |
Why?
|
| Acetylcholinesterase | 1 | 1984 | 23 | 0.000 |
Why?
|
| Weaning | 1 | 1984 | 45 | 0.000 |
Why?
|
| Receptors, Adrenergic | 1 | 1984 | 46 | 0.000 |
Why?
|
| Receptors, Dopamine | 1 | 1984 | 42 | 0.000 |
Why?
|
| Tryptophan Hydroxylase | 1 | 1984 | 30 | 0.000 |
Why?
|
| Glutamate Decarboxylase | 1 | 1984 | 44 | 0.000 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1984 | 81 | 0.000 |
Why?
|
| Acetylcholine | 1 | 1984 | 96 | 0.000 |
Why?
|
| Receptors, GABA-A | 1 | 1984 | 79 | 0.000 |
Why?
|
| Receptors, Cholinergic | 1 | 1984 | 84 | 0.000 |
Why?
|
| Tryptophan | 1 | 1984 | 127 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1984 | 600 | 0.000 |
Why?
|
| Serotonin | 1 | 1984 | 264 | 0.000 |
Why?
|
| Aging | 2 | 1984 | 1582 | 0.000 |
Why?
|
| Tyrosine | 1 | 1984 | 498 | 0.000 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1984 | 269 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1984 | 875 | 0.000 |
Why?
|
| Photic Stimulation | 1 | 1982 | 259 | 0.000 |
Why?
|
| Electroretinography | 1 | 1980 | 116 | 0.000 |
Why?
|
| Synaptosomes | 1 | 1979 | 37 | 0.000 |
Why?
|
| Subcellular Fractions | 1 | 1979 | 201 | 0.000 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1979 | 90 | 0.000 |
Why?
|
| Pregnancy | 2 | 1980 | 7573 | 0.000 |
Why?
|
| Fetus | 1 | 1979 | 601 | 0.000 |
Why?
|